Although biotech stocks nose-dived in the last quarter, the NASDAQ Biotech Index still returned a double-digit increase year on year. Compared with 2016, mergers and acquisition were down (just 54 in total), follow-on financings were up and initial public offerings (IPOs) raised similar totals in funding. But it was venture capital investment that continued to gorge the sector, with a few companies raising eye-popping amounts—all in all, the sector raised just short of $16 billion in risk capital.

Stock market performance

Global biotech initial public offerings

Global biotech venture capital investment

Global biotech industry financing

Notable 2017 deals